CO2023009615A2 - Anticuerpos multiespecíficos que tienen especificidad para il-4r e il-31 - Google Patents

Anticuerpos multiespecíficos que tienen especificidad para il-4r e il-31

Info

Publication number
CO2023009615A2
CO2023009615A2 CONC2023/0009615A CO2023009615A CO2023009615A2 CO 2023009615 A2 CO2023009615 A2 CO 2023009615A2 CO 2023009615 A CO2023009615 A CO 2023009615A CO 2023009615 A2 CO2023009615 A2 CO 2023009615A2
Authority
CO
Colombia
Prior art keywords
multispecific antibody
nucleic acids
relates
present
specificity
Prior art date
Application number
CONC2023/0009615A
Other languages
English (en)
Inventor
Christian Hess
Alexandre Simonin
Stefan Warmuth
Julia Tietz
Tea Gunde
Maria Johansson
Noriko Shiraishi
Yoshio Arakawa
Yoshihide Miyake
Original Assignee
Numab Therapeutics AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Numab Therapeutics AG filed Critical Numab Therapeutics AG
Publication of CO2023009615A2 publication Critical patent/CO2023009615A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

RESUMEN La presente invención se refiere a un anticuerpo multiespecífico que comprende uno o dos dominios de unión, que se unen específicamente a IL-4R (IL4R-BDs), y uno o dos dominios de unión, que se unen específicamente a IL-31 (IL31-BDs), en el cual el anticuerpo multiespecífico comprende una región Fc de inmunoglobulina. La presente invención también se refiere a ácidos nucleicos que codifican para dicho anticuerpo multiespecífico, vector(es) que comprende(n) dichos ácidos nucleicos, célula(s) hospedera(s) que comprende(n) dichos ácidos nucleicos o dicho(s) vector(es), y a un método para producir dicho anticuerpo multiespecífico. De manera adicional, la presente invención se refiere a composiciones farmacéuticas que comprenden dicho anticuerpo multiespecífico y a métodos de uso de las mismas.
CONC2023/0009615A 2020-12-23 2023-07-19 Anticuerpos multiespecíficos que tienen especificidad para il-4r e il-31 CO2023009615A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20216957.9A EP4019547A1 (en) 2020-12-23 2020-12-23 Multispecific antibodies having specificity for il-4r and il-31
PCT/EP2021/087561 WO2022136669A1 (en) 2020-12-23 2021-12-23 Multispecific antibodies having specificity for il-4r and il-31

Publications (1)

Publication Number Publication Date
CO2023009615A2 true CO2023009615A2 (es) 2023-08-28

Family

ID=73857084

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2023/0009615A CO2023009615A2 (es) 2020-12-23 2023-07-19 Anticuerpos multiespecíficos que tienen especificidad para il-4r e il-31

Country Status (14)

Country Link
EP (2) EP4019547A1 (es)
JP (1) JP2024501811A (es)
KR (1) KR20230125238A (es)
CN (3) CN116888151A (es)
AU (1) AU2021405058A1 (es)
CA (1) CA3205036A1 (es)
CL (1) CL2023001888A1 (es)
CO (1) CO2023009615A2 (es)
CR (1) CR20230309A (es)
DO (1) DOP2023000130A (es)
EC (1) ECSP23053070A (es)
IL (1) IL303174A (es)
TW (1) TW202241966A (es)
WO (1) WO2022136669A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL310962A (en) 2021-08-23 2024-04-01 Regeneron Pharma Methods for treating atopic dermatitis by administering an IL-4R antagonist
US20230220089A1 (en) 2021-12-30 2023-07-13 Regeneron Pharmaceuticals, Inc. Methods for attenuating atopic march by administering an il-4/il-13 antagonist
US20240034798A1 (en) 2022-07-08 2024-02-01 Regeneron Pharmaceuticals, Inc. Methods for treating eosinophilic esophagitis by administering an il-4r antagonist
WO2024061279A1 (en) * 2022-09-22 2024-03-28 Biosion Inc. Recombinant bispecific antibodies targeting tslp and il4r

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5013653A (en) 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
JPH02500329A (ja) 1987-05-21 1990-02-08 クリエイテイブ・バイオマリキユールズ・インコーポレーテツド ターゲット化多機能蛋白質
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
ES2202310T3 (es) 1991-12-13 2004-04-01 Xoma Corporation Metodos y materiales para la preparacion de dominios variables de anticuerpos modificados y sus usos terapeuticos.
DE19819846B4 (de) 1998-05-05 2016-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Multivalente Antikörper-Konstrukte
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
JP2006504971A (ja) 2002-11-01 2006-02-09 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・コロラド，ア・ボディー・コーポレイト マトリックス支援レーザー脱離イオン化−飛行時間型質量分析によるタンパク質アイソフォームの定量的解析
RU2009111884A (ru) * 2006-09-01 2010-10-10 Займоджинетикс, Инк. (Us) Последовательности вариабельных областей моноклональных антител против il-31 и способы использования
PL2892927T3 (pl) 2012-09-07 2018-11-30 Regeneron Pharmaceuticals, Inc. Sposoby leczenia atopowego zapalenia skóry przez podawanie antagonisty IL-4R
EP3459968A1 (en) 2017-09-20 2019-03-27 Numab Innovation AG Novel stable antibody variable domain framework combinations
CN111494625B (zh) * 2018-12-25 2022-06-21 江苏荃信生物医药股份有限公司 用于治疗il-4和/或il-13介导的信号转导相关的疾病的药物组合物

Also Published As

Publication number Publication date
EP4019547A1 (en) 2022-06-29
WO2022136669A1 (en) 2022-06-30
TW202241966A (zh) 2022-11-01
CN116848134A (zh) 2023-10-03
CA3205036A1 (en) 2022-06-30
EP4267613A1 (en) 2023-11-01
CR20230309A (es) 2023-10-09
DOP2023000130A (es) 2023-09-15
ECSP23053070A (es) 2023-08-31
CN116940596A (zh) 2023-10-24
IL303174A (en) 2023-07-01
KR20230125238A (ko) 2023-08-29
CL2023001888A1 (es) 2023-12-15
CN116888151A (zh) 2023-10-13
AU2021405058A1 (en) 2023-06-29
JP2024501811A (ja) 2024-01-16

Similar Documents

Publication Publication Date Title
CO2023009615A2 (es) Anticuerpos multiespecíficos que tienen especificidad para il-4r e il-31
ECSP17054182A (es) Anticuerpos anti-CD3, anticuerpos anti-CD123 y anticuerpos biespecíficos que se unen específicamente a CD3 y/o CD123
EA202090247A1 (ru) Антитела против cd166 и их применения
ECSP20024555A (es) Anticuerpos especificos para cd47 y pd-l1
CL2023002597A1 (es) Proteínas de unión al antígeno bispecífico de anti-tl1a/anti-tnf-alfa
PE20191463A1 (es) Anticuerpos biespecificos de union especifica pd1 y lag3
EA201892691A1 (ru) Однодоменный белок, связывающий сывороточный альбумин
UA117575C2 (uk) Антитіло, яке специфічно зв'язується з il-17a та його застосування
EA201892522A1 (ru) Днк-моноклональные антитела, нацеленные на молекулы контрольных точек
BR112018000696A2 (pt) ?anticorpo, métodos para reduzir e para aumentar a afinidade de ligação de um anticorpo que se liga ao cd3 humano, para tratar e para diagnosticar uma doença, para produzir um anticorpo e para detectar a presença de antígeno de cd3, construto de ácido nucleico, vetor de expressão, célula hospedeira, composição, e, kit?
EA202092735A1 (ru) Антагонизирующее cd73 антитело
BR112016014284A2 (pt) anticorpo caninizado isolado ou um fragmento de ligação de antígeno do mesmo, ácido nucleico isolado, vetor de expressão, célula hospedeira, composição farmacêutica, e, métodos para aumentar a atividade de uma célula imune e para produzir um anticorpo caninizado ou fragmento de ligação de antígeno do mesmo
BR112015025306A2 (pt) anticorpo biespecífico, anticorpos, composição farmacêutica, uso do anticorpo biespecífico, sequência de ácido nucleico, vetor de expressão, célula hospedeira procariótica ou eucariótica e método de produção de um anticorpo
BR112014009030A2 (pt) anticorpo de ligação a antígenos múltiplos estável
EA201491599A1 (ru) Антитела к матриксной металлопротеиназе 9
BR112012006492A2 (pt) proteína de fusão de anticorpo multivalente, e, ligação de albumina
JP2015527365A5 (es)
MX2014010449A (es) Anticuerpos a metaloproteinasa de matriz 9.
CL2021002792A1 (es) Anticuerpo monoclonal que se une específicamente a gitr
BR112012010266A2 (pt) anticorpo anti-fractalquina ou fragmento de ligação a fkn do mesmo, composição farmacêutica, ácido nucleico, vetor, célula hospedeira, métodos para preparar um anticorpo anti-fractalquina ou fragmento de ligação a fkn do mesmo, e para tratar um distúrbio inflamatório, e, uso de um anticorpo ou fragmento de ligação a fkn do mesmo
MX2021010281A (es) Proteinas de enlace a antigenos que se enlazan al bcma.
BR112015017981A2 (pt) anticorpo humano específico para metapneumovírus humano, ou fragmento de ligação de antígeno do mesmo, seu uso e composição farmacêutica o compreendendo, bem como ácido nucleico isolado, vetor de expressão recombinante e célula hospedeira
EA201691414A1 (ru) Антитела к матриксной металлопротеиназе 9 и способы их применения
BR112023023480A2 (pt) Uso de anticorpo anti-ctla-4
AR117961A1 (es) Proteínas de unión multiespecíficas basadas en pseudofab